Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 03, 2024
Jun. 21, 2023
Jan. 31, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Sep. 30, 2024
Mar. 31, 2024
Jun. 23, 2021
Agreements                  
Payments of consideration under RPAs, AAAs and CPPAs         $ 53,000 $ 14,650      
Contingent consideration under RPAs, AAAs, and CPPAs       $ 3,000 3,000 7,000      
Long-term royalty and commercial payment receivables under the cost recovery method       55,936 55,936 57,952      
Receipts under RPAs, AAAs, and CPPAs         29,248 13,956      
Short-term royalty and commercial payment receivables under the cost recovery method       413 413 14,215      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement                  
Agreements                  
Payments of consideration under RPAs, AAAs and CPPAs   $ 5,000 $ 1,000 1,000          
Maximum regulatory and commercial sales milestone payments   6,000              
Maximum regulatory milestone payments   5,000              
Maximum commercial sales milestone payments   1,000              
Long-term royalty and commercial payment receivables under the cost recovery method   6,000              
Amount of regulatory milestone payment removed $ 4,000                
Receipts under RPAs, AAAs, and CPPAs         2,200        
Short-term royalty and commercial payment receivables under the cost recovery method       400 400        
Allowance for credit losses       0 0 0      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones                  
Agreements                  
Payments of consideration under RPAs, AAAs and CPPAs     $ 1,000   1,000        
Contingent consideration under RPAs, AAAs, and CPPAs   $ 1,000   0 0 $ 1,000   $ 0  
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Sales-based milestones                  
Agreements                  
Payments of consideration under RPAs, AAAs and CPPAs       1,000          
Contingent consideration under RPAs, AAAs, and CPPAs       $ 0 $ 0   $ 1,000    
Long-term royalty and commercial payment receivables under the cost recovery method             $ 1,000    
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Aldoxorubicin | Regulatory milestones                  
Agreements                  
Contingent consideration under RPAs, AAAs, and CPPAs $ 0               $ 0